A phase I and pharmacokinetic study of CBT-1 as a multidrug resistance modulator in the treatment of patients with advanced cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 13, Issue 2, 1998, Pages 71-80

  Oldham, Robert K ^a   Reid, William K ^a   Preisler, Harvey D ^b   Barnett, Daryl ^c  

^a American Patient Service   (United States)

^b RUSH CANCER INSTITUTE   (United States)

^c CBA Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBT 1; DOXORUBICIN; NATURAL PRODUCT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIDRUG RESISTANCE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; VOMITING;

EID: 0031978273     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1998.13.71     Document Type: Article

References (22)

1. Pinedo HM and Giaccone G P-glycoprotein: a marker of cancer cell behavior. New Engl J Med 1995;333. 1417-1419.
2. Beck W, Cirtain M, Danks M, Felsted R, Safa A, Wolverton J, Suttle D, and Trent J. Pharmacological, molecular and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. Cancer Res 1987: 47:5455-5460.
3. Biedler J and Meyers M. Multidrug resistance (Vinca alkaloids, actinomycin D, and anthracycline antibiotics). In: R Gupta (ed.), Drug Resistance in Mammalian Cells, Vol. 2, Anticancer and Other Drugs, pp. 125-140, 1989. Boca Raton, FL: CRC Press.
4. Gerlach J, Kartner N, Bell D, and Ling V. Multidrug resistance. Cancer Surv 1986;5:25-46.
5. Fojo A, Ueda K, Slamon D, Poplack D, Gottesman M, and Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84:265-269.
6. Yuen A and Sikic B. Multidrug resistance in lymphomas. J Clin Oncol 1994;12:2453-2459.
7. Fojo A, Shen D-W, Mickley L, Pastan I, and Gottesman M. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug resistance gene. J Clin Oncol 1987;5:1922-1927.
8. Goldstein I, Galski H, Fojo A, Willingham M, Lai S-L, Gazdar A, Pirker R, Green A, Crist W, Brodeur G, Lieber M, Cossman J, Gottesman M, and Pastan I. Expression of a multidrug resistance gene in human tumors. J Natl Cancer Inst 1989;81:116-124.
9. Tsuruo T, Iida H, Tsukagoshi S, and Sakurai Y. Increased accumulation of vincristine and Adriamycin in drug resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 1982;42:4730-4733.
10. Pennock G, Dalton W, Roeske W, Appleton C, Mosley K, Plezia P, Miller T, and Salmon S. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 1991;83:105-110.
11. Samuels B, Mick R, Vogelzang N, Williams S, Schilsky R, Safa A, O'Brien S, and Ratain M. Modulation of vinblastine resistance with cyclosporine: a Phase I study. Clin Pharmacol Ther 1993;54:421-429.
12. Trump D, Smith D, Ellis P, Rogers M, Schold S, Winer E, Panella T, Jordan V, and Fine R. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine. J Natl Cancer Inst 1992;84:1811-1816.
13. Giaccone G, Linn SC, Welink J, Catimel G, Steltjes H, van der Vijgh WJF, Eeltink C, Vermorken JB, and Pinedo HM. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 1997;3:2005-2015.
14. Samuels BL, Hollis DR, Rosner GL, Trump DL, Shapiro CL, Vogelzang NJ, and Schilsky RL. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Clin Cancer Res 1997;3:1977-1984.
15. Simon R Designs for efficient clinical trials. Oncology 1989;3:43-49.
16. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, and Sikic IB. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. Journ Clin Oncol 1994,12:835-842.
17. CBA Research Inc. Data on file, 1998.
18. Kerr DJ, Graham J, Cummings J, Morrison JG, Thompson GG, Brodie MJ, and Kaye SB. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1986;18:239-242.
19. Lum BL, Kaubish S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, and Sikic BL Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992;10: 1635-1642.
20. Speeg KV and Maldonado AL. Effect of the nonimmunosuppressive cyclosporine analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo. Cancer Chemother Pharmacol 1994;34:133-136.
21. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, and Bleehen NM. Phase I study of etoposide with SDZ PSC-833 as a modulator of multidrug resistance in patients with cancer J Clin Oncol 1996;14:610-618.
22. Fisher GA, Lum BL, Hausdorff J, And Sikic BI Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 1996;32A:1082-1088.